Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle

  • Coiras, Mayte
  • Bermejo, Mercedes
  • Descours, Benjamin
  • Mateos, Elena
  • García-Pérez, Javier
  • Lopez-Huertas, Maria Rosa
  • Lederman, Michael M
  • Benkirane, Monsef
  • Alcamí, José
HIV-1 post-integration latency in CD4+ lymphocytes is responsible for viral persistence despite treatment, but mechanisms involved in the establishment of latent viral reservoirs are not fully understood. We determined that both interleukin 2 (IL-2) and IL-7 induced SAMHD1 phosphorylation in T592, abrogating its antiviral activity. However, IL-7 caused a much more profound stimulatory effect on HIV-1 reverse transcription and integration than IL-2 that required chemokine co-stimulation. Both cytokines barely induced transcription due to low NF-κB induction, favoring the establishment of latent reservoirs. Effect of IL-7 on SAMHD1 phosphorylation was confirmed in IL-7-treated patients (ACTG 5214 study). Dasatinib--a tyrosine-kinase inhibitor--blocked SAMHD1 phosphorylation induced by IL-2 and IL-7 and restored HIV-1 restriction. We propose that γc-cytokines play a major role in the reservoir establishment not only by driving homeostatic proliferation but also by increasing susceptibility of CD4+ lymphocytes to HIV-1 infection through SAMHD1 inactivation.
Repisalud
Publicación Artículo científico (JournalArticle)

Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors

  • Bermejo, Mercedes
  • Ambrosioni, Juan
  • Bautista, Guiomar
  • Climent, Núria
  • Mateos, Elena
  • Rovira, Cristina
  • Rodriguez‑Mora, Sara
  • Lopez-Huertas, Maria Rosa
  • García-Gutiérrez, Valentín
  • Steegmann, Juan Luis
  • Duarte, Rafael
  • Cervantes, Francisco
  • Plana, Montserrat
  • Miró, José María
  • Alcamí, José
  • Coiras, Mayte
Current antiretroviral treatment (ART) may control HIV-1 replication but it cannot cure the infection due to the formation of a reservoir of latently infected cells. CD4+ T cell activation during HIV-1 infection eliminates the antiviral function of the restriction factor SAMHD1, allowing proviral integration and the reservoir establishment. The role of tyrosine kinases during T-cell activation is essential for these processes. Therefore, the inhibition of tyrosine kinases could control HIV-1 infection and restrict the formation of the reservoir. A family of tyrosine kinase inhibitors (TKIs) is successfully used in clinic for treating chronic myeloid leukemia (CML). The safety and efficacy against HIV-1 infection of five TKIs was assayed in PBMCs isolated from CML patients on prolonged treatment with these drugs that were infected ex vivo with HIV-1. We determined that the most potent and safe TKI against HIV-1 infection was dasatinib, which preserved SAMHD1 antiviral function and avoid T-cell activation through TCR engagement and homeostatic cytokines. Imatinib and nilotinib showed lower potency and bosutinib was quite toxic in vitro. Ponatinib presented similar profile to dasatinib but as it has been associated with higher incidence of arterial ischemic events, dasatinib would be the better choice of TKI to be used as adjuvant of ART in order to avoid the establishment and replenishment of HIV-1 reservoir and move forward towards an HIV cure.
Repisalud
Publicación Artículo científico (JournalArticle)

Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication

  • Mateos, Elena
  • Lopez, Juan Antonio
  • Calvo, Enrique
  • Terrón-Orellana, Maria Carmen
  • Luque, Daniel
  • Alcamí, José
  • Coiras, Mayte
  • Lopez-Huertas, Maria Rosa
  • Rodriguez‑Mora, Sara
  • Moran, María
  • Martín, Miguel Ángel
  • Muriaux, Delphine
HIV-1 replication results in mitochondrial damage that is enhanced during antiretroviral therapy (ART). The onset of HIV-1 replication is regulated by viral protein Tat, a 101-residue protein codified by two exons that elongates viral transcripts. Although the first exon of Tat (aa 1–72) forms itself an active protein, the presence of the second exon (aa 73–101) results in a more competent transcriptional protein with additional functions. Results: Mitochondrial overall functions were analyzed in Jurkat cells stably expressing full-length Tat (Tat101) or one-exon Tat (Tat72). Representative results were confirmed in PBLs transiently expressing Tat101 and in HIV-infected Jurkat cells. The intracellular expression of Tat101 induced the deregulation of metabolism and cytoskeletal proteins which remodeled the function and distribution of mitochondria. Tat101 reduced the transcription of the mtDNA, resulting in low ATP production. The total amount of mitochondria increased likely to counteract their functional impairment. These effects were enhanced when Tat second exon was expressed. Conclusions: Intracellular Tat altered mtDNA transcription, mitochondrial content and distribution in CD4+ T cells. The importance of Tat second exon in non-transcriptional functions was confirmed. Tat101 may be responsible for mitochondrial dysfunctions found in HIV-1 infected patients.
Repisalud
Publicación Artículo científico (JournalArticle)

Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells

  • Bermejo, Mercedes
  • Lopez-Huertas, Maria Rosa
  • García-Pérez, Javier
  • Climent, Núria
  • Descours, Benjamin
  • Ambrosioni, Juan
  • Mateos, Elena
  • Rodriguez‑Mora, Sara
  • Rus-Bercial, Lucía
  • Benkirane, Monsef
  • Miró, José María
  • Plana, Montserrat
  • Alcamí, José
  • Coiras, Mayte
Massive activation of infected CD4+ T cells during acute HIV-1 infection leads to reservoir seeding and T-cell destruction. During T-cell activation, the antiviral effect of the innate factor SAMHD1 is neutralized through phosphorylation at T592, allowing HIV-1 infection. Dasatinib, a tyrosine kinase inhibitor currently used for treating chronic myeloid leukemia, has been described to control HIV-1 replication through its negative effect on T-cell proliferation and viral entry. We demonstrate that Dasatinib can actually interfere with SAMHD1 phosphorylation in human peripheral blood lymphocytes, preserving its antiviral activity against HIV-1. Dasatinib prevented SAMHD1 phosphorylation in vitro and ex vivo, impairing HIV-1 reverse transcription and proviral integration. This was the major mechanism of action because the presence of Vpx, which degrades SAMHD1, in HIV-1 virions impeded the inhibitory effect of Dasatinib on HIV-1 replication. In fact, infection with VSV-pseudotyped HIV-1 virions and fusion of BlaM-Vpr-containing HIV-1 viruses with activated PBMCs in the presence of Dasatinib suggested that Dasatinib was not acting at fusion level. Finally, PBMCs from patients on chronic treatment with Dasatinib showed a lower level of SAMHD1 phosphorylation in response to activating stimuli and low susceptibility to HIV-1 infection ex vivo. Consequently, Dasatinib is a compound currently used in clinic that preserves the antiviral function of SAMHD1. Using Dasatinib as adjuvant of antiretroviral therapy during early primary HIV-1 infection would contribute to reduce viral replication and spread, prevent reservoir seeding, and preserve CD4 counts and CTL responses. These events would create a more favorable virologic and immunologic environment for future interventional studies aiming at HIV-1 eradication.
Repisalud
Publicación Artículo científico (JournalArticle)

Functional Consequences for Apoptosis by Transcription Elongation Regulator 1 (TCERG1)-Mediated Bcl-x and Fas/CD95 Alternative Splicing

  • Montes, Marta
  • Coiras, Mayte
  • Becerra, Soraya
  • Moreno-Castro, Cristina
  • Mateos, Elena
  • Majuelos, Jara
  • Oliver, F Javier
  • Hernández-Munain, Cristina
  • Alcamí, José
  • Suñé, Carlos
Here, we present evidence for a specific role of the splicing-related factor TCERG1 in regulating apoptosis in live cells by modulating the alternative splicing of the apoptotic genes Bcl-x and Fas. We show that TCERG1 modulates Bcl-x alternative splicing during apoptosis and its activity in Bcl-x alternative splicing correlates with the induction of apoptosis, as determined by assessing dead cells, sub-G1-phase cells, annexin-V binding, cell viability, and cleavage of caspase-3 and PARP-1. Furthermore, the effect of TCERG1 on apoptosis involved changes in mitochondrial membrane permeabilization. We also found that depletion of TCERG1 reduces the expression of the activated form of the pro-apoptotic mitochondrial membrane protein Bak, which remains inactive by heterodimerizing with Bcl-xL, preventing the initial step of cytochrome c release in Bak-mediated mitochondrial apoptosis. In addition, we provide evidence that TCERG1 also participates in the death receptor-mediated apoptosis pathway. Interestingly, TCERG1 also modulates Fas/CD95 alternative splicing. We propose that TCERG1 sensitizes a cell to apoptotic agents, thus promoting apoptosis by regulating the alternative splicing of both the Bcl-x and Fas/CD95 genes. Our findings may provide a new link between the control of alternative splicing and the molecular events leading to apoptosis.
Repisalud
Publicación Artículo científico (JournalArticle)

Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells

  • Sanchez-Del Cojo, Maria
  • Díez-Fuertes, Francisco
  • Rodriguez‑Mora, Sara
  • Bermejo, Mercedes
  • Lopez-Campos, Guillermo
  • Mateos, Elena
  • Jiménez-Tormo, Laura
  • Gómez-Esquer, Francisco
  • Díaz-Gil, Gema
  • Alcamí, José
  • Coiras, Mayte
  • Lopez-Huertas, Maria Rosa
HIV-1 induces changes in the miRNA expression profile of infected CD4+ T cells that could improve viral replication. HIV-1 regulator Tat modifies the cellular gene expression and has been appointed as an RNA silencing suppressor. Tat is a 101-residue protein codified by two exons that regulates the elongation of viral transcripts. The first exon of Tat (amino acids 1-72) forms the transcriptionally active protein Tat72, but the presence of the second exon (amino acids 73-101) results in a more competent regulatory protein (Tat101) with additional functions. Intracellular, full-length Tat101 induces functional and morphological changes in CD4+ T cells that contribute to HIV-1 pathogenesis such as delay in T-cell proliferation and protection against FasL-mediated apoptosis. But the precise mechanism by which Tat produces these changes remains unknown. We analyzed how the stable expression of intracellular Tat101 and Tat72 modified the miRNA expression profile in Jurkat cells and if this correlated with changes in apoptotic pathways and cell cycle observed in Tat-expressing cells. Specifically, the enhanced expression of hsa-miR-21 and hsa-miR-222 in Jurkat-Tat101 cells was associated with the reduced expression of target mRNAs encoding proteins related to apoptosis and cell cycle such as PTEN, PDCD4 and CDKN1B. We developed Jurkat cells with stable expression of hsa-miR-21 or hsa-miR-222 and observed a similar pattern to Jurkat-Tat101 in resistance to FasL-mediated apoptosis, cell cycle arrest in G2/M and altered cell morphology. Consequently, upregulation of hsa-miR-21 and hsa-miR-222 by Tat may contribute to protect against apoptosis and to anergy observed in HIV-infected CD4+ T cells.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

A machine learning approach for type 2 diabetes diagnosis and prognosis using tailored heterogeneous feature subsets

  • Navarro Cerdan, José Ramón|||0000-0002-6692-5941
  • Arlandis, Joaquim|||0000-0003-2472-8883
  • Llobet Azpitarte, Rafael|||0000-0002-8278-9740
  • Perez-Cortes, Juan-Carlos|||0000-0001-6506-090X
  • Pons-Suñer, Pedro
  • Arnal, Laura
  • Lara-Hernández, Francisco
  • Moya-Valera, Celeste
  • Quiroz-Rodriguez, Maria Elena
  • Rojo-Martinez, Gemma
  • Valdés, Sergio
  • Montanya, Eduard
  • Calle-Pascual, Alfonso L.
  • Franch-Nadal, Josep
  • Delgado, Elias
  • Luis Castaño
  • Ana-Bárbara García-García
  • Chaves-Martinez, Felipe Javier
[EN] Type 2 diabetes (T2D) is becoming one of the leading health problems in Western societies, diminishing quality of life and consuming a significant share of healthcare resources. This study presents machine learning models for T2D diagnosis and prognosis, developed using heterogeneous data from a Spanish population dataset (Di@bet.es study). The models were trained exclusively on individuals classified as controls and undiagnosed diabetics, ensuring that the results are not influenced by treatment effects or behavioral changes due to disease awareness. Two data domains are considered: environmental (patient lifestyle questionnaires and measurements) and clinical (biochemical and anthropometric measurements). The preprocessing pipeline consists of four key steps: geospatial data extraction, feature engineering, missing data imputation, and quasiconstancy filtering. Two working scenarios (Environmental and Healthcare) are defined based on the features used, and applied to two targets (diagnosis and prognosis), resulting in four distinct models. The feature subsets that best predict the target have been identified based on permutation importance and sequential backward selection, reducing the number of features and, consequently, the cost of predictions. In the Environmental scenario, models achieved an AUROC of 0.86 for diagnosis and 0.82 for prognosis. The Healthcare scenario performed better, with an AUROC of 0.96 for diagnosis and 0.88 for prognosis. A partial dependence analysis of the most relevant features is also presented. An online demo page showcasing the Environmental and Healthcare T2D prognosis models is available upon request., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The activities described in this document are part of the Cervera Network of Excellence in Data-Based Enabling Technologies (AI4ES) project, which is co-financed by the Center for Industrial Technological Development, E.P.E. (CDTI) and by the European Union through the Next Generation EU Fund, within the Cervera aid program for Technology Centers by the CDTI, with file number CER-20211030. This research was also funded by Generalitat Valenciana through IVACE and the European Union through FEDER funds, PANAKEIA project IMDEEA/2023/92. This work was also funded by Generalitat Valenciana through IVACE through a grant to support ITI s activity in independent research and development, research results dissemination and knowledge and technology transfer to business under project IMAMCA/2023/11. Research grants PI17/00544 and PI21/00506 from Ministerio de Ciencia e Innovación and Instituto de Salud Carlos III (ISCIII). CIBERDEM (CB07/08/0018) is part of CIBER (Consorcio Centro de Investigación Biomédica en Red) funded by ISCIII. Both research projects and CIBER are co-funded by the European Union (European Regional Development Fund (ERDF) A way to build Europe ). Funding for open access charge: CRUE-Universitat Politècnica de València.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Gene-environment interaction analysis of redox-related metals and genetic variants with plasma metabolic patterns in a general population from Spain: The Hortega Study

  • Galvez-Fernandez, Marta
  • Domingo-Relloso, Arce
  • Rodríguez-Hernández, Zulema
  • Gonzalez-Marrachelli, Vannina
  • Grau-Perez, Maria
  • Morales-Tatay, José M.
  • Amigo, Nuria
  • Garcia-Barrera, Tamara
  • Gomez-Ariza, Jose L.
  • Chaves, F. Javier
  • Garcia-Garcia, Ana Barbara
  • Melero, Rebeca
  • Tellez-Plaza, Maria
  • Sanchez Saez, Francisco|||0000-0002-3011-9884
  • Tarazona, Sonia|||0000-0001-5346-1407
[EN] Background: Limited studies have evaluated the joint influence of redox-related metals and genetic variation on metabolic pathways. We analyzed the association of 11 metals with metabolic patterns, and the interacting role of candidate genetic variants, in 1145 participants from the Hortega Study, a population-based sample from Spain. Methods: Urine antimony (Sb), arsenic, barium (Ba), cadmium (Cd), chromium (Cr), cobalt (Co), molybdenum (Mo) and vanadium (V), and plasma copper (Cu), selenium (Se) and zinc (Zn) were measured by ICP-MS and AAS, respectively. We summarized 54 plasma metabolites, measured with targeted NMR, by estimating metabolic principal components (mPC). Redox-related SNPs (N = 291) were measured by oligo-ligation assay. Results: In our study, the association with metabolic principal component (mPC) 1 (reflecting non-essential and essential amino acids, including branched chain, and bacterial co-metabolism versus fatty acids and VLDL subclasses) was positive for Se , Zn, but inverse for Cu, arsenobetaine-corrected arsenic (As) and Sb. The association with mPC2 (reflecting essential amino acids, including aromatic , bacterial co-metabolism) was inverse for Se, Zn and Cd. The association with mPC3 (reflecting LDL subclasses) was positive for Cu, Se and Zn, but inverse for Co. The association for mPC4 (reflecting HDL subclasses) was positive for Sb, but inverse for plasma Zn. These associations were mainly driven by Cu and Sb for mPC1; Se, Zn and Cd for mPC2; Co, Se and Zn for mPC3; and Zn for mPC4. The most SNP-metal interacting genes were NOX1, GSR, GCLC, AGT and REN. Co and Zn showed the highest number of interactions with genetic variants associated to enriched endocrine, car-diovascular and neurological pathways. Conclusions: Exposures to Co, Cu, Se, Zn, As, Cd and Sb were associated with several metabolic patterns involved in chronic disease. Carriers of redox-related variants may have differential susceptibility to metabolic alterations associated to excessive exposure to metals., This work was supported by the Strategic Action for Research in Health sciences [CP12/03080, PI15/00071, PI10/0082, PI13/01848, PI14/00874, PI16/01402, PI21/00506 and PI11/00726] , CIBER Fisio-patologia Obesidad y Nutricion (CIBEROBN) (CIBER-02-08-2009, CB06/03 and CB12/03/30,016) , the State Agency for Research (PID2019-108973RB-C21 and C22) , the Valencia Government (GRU-POS 03/101; PROMETEO/2009/029 and ACOMP/2013/039, IDI-FEDER/2021/072 and GRISOLIAP/2021/119) , the Castilla-Leon Government (GRS/279/A/08) and European Network of Excellence Ingenious Hypercare (EPSS-037093) from the European Commission. The Strategic Action for Research in Health sciences, CIBERDEM and CIBEROBN are initiatives from Carlos III Health Institute Madrid and co-funded with European Funds for Regional Development (FEDER) . The State Agency for Research and Carlos III Health Institute belong to the Spanish Ministry of Science and Innovation. ADR received the support of a fellowship from "la Caixa"Foundation (ID 100010434) (fellowship code "LCF/BQ/DR19/11740016") . MGP received the support of a fellowship from "la Caixa" Foundation (ID 100010434, fellowship code LCFLCF/BQ/DI18/11660001) . The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer

  • Solinas, Cinzia
  • Llop-Guevara, Alba
  • Pellegrino, Benedetta
  • Pimentel, Isabel
  • Villacampa Javierre, Guillermo
  • Torres-Esquius, Sara
  • Simonetti, Sara
  • Saura Manich, Cristina
  • Balmaña, Judith
  • Serra, Violeta
Homologous recombination deficiency; Survival; Breast cancer, Deficiencia de recombinación homóloga; Supervivencia; Cáncer de mama, Deficiència de recombinació homòloga; Supervivència; Càncer de mama, Advances in breast cancer (BC) therapy are limited by the absence of well-established biomarkers for DNA-damage targeted treatments. We evaluated the predictive and prognostic value of homologous recombination repair (HRR) deficiency (HRD) by RAD51 nuclear foci and stromal tumour-infiltrating lymphocytes (TILs) in early-stage BC patients with suspected germline susceptibility. Among 291 patients, HRD by RAD51 was found in 78.4% of tumours, and 69.8% had low TILs (<30%). In 178 patients treated with neoadjuvant chemotherapy, pathologic complete response (pCR) was higher in those with HRD vs HRR-proficient (HRP) tumours (52.3% vs 36.4%); RAD51 remained independently associated with pCR (p = 0.03). Overall survival (OS) favoured HRD, with 5-year OS of 89.2% vs 82.8% in HRP (p = 0.009), with stronger evidence in triple-negative TILs-low disease (p = 0.005). These findings support RAD51-based HRD assessment as a predictive and prognostic biomarker that may guide treatment decisions in early-stage BC., We acknowledge C. Belli, F. Pedretti, A. Herencia-Ropero, M. Guzmán and O. Rodríguez for technical support. VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, the CERCA program from the Generalitat de Catalunya and patients and families for their support on this research. This study was also supported by the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). This work received funds from Asociación Española contra el cancer [AECC, LABAE16020PORTT], Institutode Salud Carlos III [PI23/00506] and the Catalan Agency AGAUR-FEDER [2021 SGR 01510 to V.S and 2022 SGR 01112 to J.B), AL-G and C.C. were supported by AECC [INVES20095LLOP, AIOC15152806CRUZ].
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Barriers of mental health treatment utilization among first-year college students, first cross-national results from the WHO World Mental Health International College Student Initiative

  • Ebert, David Daniel|||0000-0001-6820-0146
  • Mortier, Philippe|||0000-0003-2113-6241
  • Kaehlke, Fanny|||0000-0002-8189-301X
  • Bruffaerts, Ronny|||0000-0002-0330-3694
  • Baumeister, Harald
  • Auerbach, Randy P.
  • Alonso, Jordi|||0000-0001-8627-9636
  • Vilagut, Gemma|||0000-0002-3714-226X
  • Martínez, Kalina U.
  • Lochner, Christine|||0000-0002-4766-3704
  • Cuijpers, Pim|||0000-0001-5497-2743
  • Kuechler, Ann-Marie
  • Green, Jennifer|||0000-0002-3541-4989
  • Hasking, Penelope
  • Lapsley, Coral
  • Sampson, Nancy A.
  • Kessler, Ronald|||0000-0003-4831-2305
Although mental disorders and suicidal thoughts-behaviors (suicidal thoughts and behaviors) are common among university students, the majority of students with these problems remain untreated. It is unclear what the barriers are to these students seeking treatment. The aim of this study is to examine the barriers to future help-seeking and the associations of clinical characteristics with these barriers in a cross-national sample of first-year college students. As part of the World Mental Health International College Student (WMH-ICS) initiative, web-based self-report surveys were obtained from 13,984 first-year students in eight countries across the world. Clinical characteristics examined included screens for common mental disorders and reports about suicidal thoughts and behaviors. Multivariate regression models adjusted for socio-demographic, college-, and treatment-related variables were used to examine correlates of help-seeking intention and barriers to seeking treatment. Only 24.6% of students reported that they would definitely seek treatment if they had a future emotional problem. The most commonly reported reasons not to seek treatment among students who failed to report that they would definitely seek help were the preference to handle the problem alone (56.4%) and wanting to talk with friends or relatives instead (48.0%). Preference to handle the problem alone and feeling too embarrassed were also associated with significantly reduced odds of having at least some intention to seek help among students who failed to report that they would definitely seek help. Having 12-month major depression, alcohol use disorder, and suicidal thoughts and behaviors were also associated with significantly reduced reported odds of the latter outcome. The majority of first-year college students in the WMH-ICS surveys report that they would be hesitant to seek help in case of future emotional problems. Attitudinal barriers and not structural barriers were found to be the most important reported reasons for this hesitation. Experimental research is needed to determine whether intention to seek help and, more importantly, actual help-seeking behavior could be increased with the extent to which intervention strategies need to be tailored to particular student characteristics. Given that the preference to handle problems alone and stigma and appear to be critical, there could be value in determining if internet-based psychological treatments, which can be accessed privately and are often build as self-help approaches, would be more acceptable than other types of treatments to student who report hesitation about seeking treatment.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer

  • Solinas, Cinzia
  • Llop-Guevara, Alba
  • Pellegrino, Benedetta
  • Pimentel, Isabel
  • Villacampa Javierre, Guillermo
  • Torres-Esquius, Sara
  • Simonetti, Sara
  • Saura Manich, Cristina
  • Balmaña, Judith
  • Serra, Violeta
Homologous recombination deficiency; Survival; Breast cancer, Deficiencia de recombinación homóloga; Supervivencia; Cáncer de mama, Deficiència de recombinació homòloga; Supervivència; Càncer de mama, Advances in breast cancer (BC) therapy are limited by the absence of well-established biomarkers for DNA-damage targeted treatments. We evaluated the predictive and prognostic value of homologous recombination repair (HRR) deficiency (HRD) by RAD51 nuclear foci and stromal tumour-infiltrating lymphocytes (TILs) in early-stage BC patients with suspected germline susceptibility. Among 291 patients, HRD by RAD51 was found in 78.4% of tumours, and 69.8% had low TILs (<30%). In 178 patients treated with neoadjuvant chemotherapy, pathologic complete response (pCR) was higher in those with HRD vs HRR-proficient (HRP) tumours (52.3% vs 36.4%); RAD51 remained independently associated with pCR (p = 0.03). Overall survival (OS) favoured HRD, with 5-year OS of 89.2% vs 82.8% in HRP (p = 0.009), with stronger evidence in triple-negative TILs-low disease (p = 0.005). These findings support RAD51-based HRD assessment as a predictive and prognostic biomarker that may guide treatment decisions in early-stage BC., We acknowledge C. Belli, F. Pedretti, A. Herencia-Ropero, M. Guzmán and O. Rodríguez for technical support. VHIO would like to acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, the CERCA program from the Generalitat de Catalunya and patients and families for their support on this research. This study was also supported by the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). This work received funds from Asociación Española contra el cancer [AECC, LABAE16020PORTT], Institutode Salud Carlos III [PI23/00506] and the Catalan Agency AGAUR-FEDER [2021 SGR 01510 to V.S and 2022 SGR 01112 to J.B), AL-G and C.C. were supported by AECC [INVES20095LLOP, AIOC15152806CRUZ].